Related Experiment Video

Updated: Jun 8, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Effect of cardiac resynchronization therapy in patients with New York Heart Association functional class IV heart

Rutger J van Bommel1, Eva van Rijnsoever, C Jan Willem Borleffs

  • 1Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

The American Journal of Cardiology
|October 6, 2010
PubMed

Insights

Cardiac resynchronization therapy (CRT) improves heart function in severe heart failure patients (NYHA class IV). However, long-term survival remains a significant concern, highlighting the need for further research and treatment strategies.

Area of Science:

  • Cardiology
  • Heart Failure Management

Background:

  • Cardiac resynchronization therapy (CRT) is a standard treatment for heart failure patients with NYHA functional class III and IV.
  • Limited data exists on CRT efficacy in NYHA class IV patients due to their underrepresentation in clinical trials.

Purpose of the Study:

  • To evaluate the effects of CRT on clinical outcomes, left ventricular (LV) volumes, and cardiac function in patients with NYHA class IV heart failure.
  • To assess the long-term survival rates in this patient population following CRT implantation.

Main Methods:

  • A cohort of 61 patients with NYHA class IV heart failure underwent CRT implantation.
  • Clinical status, LV volumes, and ejection fraction were assessed at baseline and 6-month follow-up.
  • Long-term survival was monitored.

Main Results:

  • At 6 months, 64% of patients showed improvement based on the clinical composite score.
  • Significant improvements were observed in LV ejection fraction (22% to 28%) and LV end-systolic volume.
  • Long-term follow-up revealed high mortality rates, with 59% of patients dying during a mean of 30 months, primarily from worsening heart failure.

Conclusions:

  • CRT can improve cardiac function and reduce LV volumes in NYHA class IV heart failure patients.
  • Despite functional improvements, mortality remains high in this group, underscoring the severity of their condition.

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...